Compare Teradyne, Inc. (TER) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teradyne, Inc. vs Tango Therapeutics Inc. — how do they compare? Teradyne, Inc. trades at $345.31 (market cap $56.20B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Teradyne, Inc. is far larger — about 15× Tango Therapeutics Inc.'s market cap, and Teradyne, Inc. pays a 0.14% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Teradyne, Inc. for 37 Days and Tango Therapeutics Inc. for 0 Days on average.
| TER | TNGX | |
|---|---|---|
Market Cap | $56.20B | $3.74B |
Volume | 3,754,298 | 3,438,781 |
Sector | Technology | Health |
52-Week High | $483.84 | $32.90 |
52-Week Low | $138.09 | $7.50 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | $55.94B | $2.76B |
Dividend Yield | 0.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Teradyne (TER) trades at $380.29, down 0.93% on the day, with a bearish technical signal and support near $378. The stock shows strong fundamentals, beating earnings estimates in recent quarters, with a 25.77% net income margin and robust ROE of 36.66%. Recent news highlights expansion in AI-driven memory test solutions and strategic partnerships, positioning the company for growth in semiconductor equipment demand.
Outlook is positive with analyst consensus price target of $461.50, implying 21% upside, supported by 61% buy ratings. Risks include competitive pressures in semiconductor testing and reliance on cyclical tech spending. Earnings momentum and AI-driven demand present opportunities, but investors should monitor execution against high valuation multiples like a P/E of 52.24.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
